Kura Oncology

KURA Lead: Approved 6 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-05

Catalyst timeline

ziftomenib Ph3 topline2H 2026ziftomenib Ph3 topline, 2H 2026, thesis-defining
ziftomenib (KOMET-008) / darlifarnib +2H 2026ziftomenib (KOMET-008) / darlifarnib +, 2H 2026, notable
KO-7246 readout2H 2026KO-7246 readout, 2H 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

KOMZIFTI

ziftomenib

Small Molecule Target: menin, KMT2A, FLT3, NPM1

Acute Myeloid Leukemia Approved Phase 1/2 trial oral Kyowa Kirin NCT04067336
Pediatric Acute Leukemia Phase 1 oral Blood Cancer United NCT04067336
Gastrointestinal Stromal Tumor Phase 1 oral Kyowa Kirin NCT06655246
Acute Lymphoblastic Leukemia Phase 1 Phase 1/2 trial oral Kyowa Kirin NCT04067336

KO-7246

Small Molecule Target: menin

darlifarnib

Small Molecule Target: farnesyl transferase, RHEB, mTORC1, VEGFR

Renal Cell Carcinoma Phase 1 oral NCT06026410
Undisclosed indication Phase 1

darlifarnib

KO-2806

Small Molecule Target: farnesyl transferase, KRAS G12C, RHEB, mTORC1

Non-Small Cell Lung Cancer Phase 1 oral Mirati Therapeutics
Colorectal Cancer Phase 1 oral Mirati Therapeutics NCT06026410
Pancreatic Ductal Adenocarcinoma Phase 1 oral Mirati Therapeutics NCT06026410

Discontinued (1)

tipifarnib — Head and Neck Squamous Cell Carcinoma · KURRENT-HN trial completed in Q3 2025; evaluating data generation options for next steps with darlifarnib combination

Biotech Distilled coverage (6)

2026-08-13 UPDATE: Kura Oncology (KURA) - The Launch Wins the Head-to-Head 🔒 Paid
2026-07-28 UPDATE: Kura Oncology (KURA) - The Call Option Grows Teeth 🔒 Paid
2026-06-11 UPDATE: Kura Oncology (KURA) — The Binary Prints, Three Days Early
2026-06-02 UPDATE: Kura Oncology (KURA) — The Ven/Aza Arm Gets Its Receipt
2026-05-30 UPDATE: Kura Oncology (KURA) — Subscriber Update
2026-05-15 Kura Oncology (KURA) - Scientific Deep Dive for Ziftomenib and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.